Literature DB >> 17854725

The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.

Max Hopwood1, Carla Treloar.   

Abstract

Exploration of patients' illicit drug use during treatment for hepatitis C virus (HCV) infection is largely absent from the clinical literature. This paper explores injecting and other illicit drug use among people receiving interferon-based treatment for HCV infection, from the perspective of one group of health professionals. Data are presented from a qualitative study of six health professionals responsible for managing HCV treatment regimens at three major metropolitan hospitals across Sydney, Australia. During semi-structured in-depth interviews, participants discussed patients' use of injected and non-injected illicit drugs while coping with a demanding therapeutic regimen. Health professionals highlighted the socially conservative environment of healthcare and its negative perceptions of illicit drug users. Also discussed are the management of people who inject during treatment and the efficacy of cannabis to reduce side effects. The findings of this study indicate that while the health professionals adopted a harm reduction approach to patients' illicit drug use during HCV treatment, information regarding the risks and benefits of illicit drug use is silenced in this context. While ever prohibition remains Australia's illicit drug policy this situation appears unlikely to change. Research which investigates the extent of illicit drug use during HCV treatment, the risks and benefits associated with their use in this context, and the harms of perpetuating a duplicitous healthcare system is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854725     DOI: 10.1016/j.drugpo.2006.12.018

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  8 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Cohort profile: The provincial substance use disorder cohort in British Columbia, Canada.

Authors:  Fahmida Homayra; Lindsay A Pearce; Linwei Wang; Dimitra Panagiotoglou; Tamunoibim F Sambo; Neale Smith; Rachael McKendry; Bonnie Wilson; Ronald Joe; Ken Hawkins; Rolando Barrios; Craig Mitton; Bohdan Nosyk
Journal:  Int J Epidemiol       Date:  2021-01-23       Impact factor: 7.196

3.  Non-disclosure of drug use in outpatient health care settings: Findings from a prospective cohort study in Vancouver, Canada.

Authors:  Lindsay A Pearce; Fahmida Homayra; Laura M Dale; Soroush Moallef; Brittany Barker; Alexa Norton; Kanna Hayashi; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2020-07-27

Review 4.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.

Authors:  Magdalena Harris; Tim Rhodes
Journal:  Harm Reduct J       Date:  2013-05-07

Review 5.  Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.

Authors:  Viktor Mravčík; Lisa Strada; Josef Stolfa; Vladimir Bencko; Teodora Groshkova; Jens Reimer; Bernd Schulte
Journal:  Patient Prefer Adherence       Date:  2013-10-17       Impact factor: 2.711

Review 6.  Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.

Authors:  Zachary C Rich; Carissa Chu; Jessica Mao; Kali Zhou; Weiping Cai; Qingyan Ma; Paul Volberding; Joseph D Tucker
Journal:  BMC Public Health       Date:  2016-09-20       Impact factor: 3.295

7.  Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.

Authors:  Issifou Yaya; Perrine Roux; Fabienne Marcellin; Linda Wittkop; Laure Esterle; Bruno Spire; Stéphanie Dominguez; Boni Armand Elegbe; Lionel Piroth; Philippe Sogni; Dominique Salmon-Ceron; Maria Patrizia Carrieri
Journal:  PLoS One       Date:  2018-07-05       Impact factor: 3.240

8.  From client to co-worker: a case study of the transition to peer work within a multi-disciplinary hepatitis c treatment team in Toronto, Canada.

Authors:  Paula Tookey; Kate Mason; Jennifer Broad; Marty Behm; Lise Bondy; Jeff Powis
Journal:  Harm Reduct J       Date:  2018-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.